Skip to main content

Advertisement

SpringerLink
Log in

Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

To analyze the clinical characteristics and prognostic factors in patients with glioma in an academic institute in China. From October 2004 to August 2010, total 1,285 patients were diagnosed as glioma at the Glioma Center of Beijing Tiantan Hospital. Clinical and molecular pathology features and survival rates were analyzed. The median overall survival (OS) times were 78.1, 37.6 and 14.4 months for low-grade glioma (WHO grade II), anaplastic glioma (WHO grade III) and glioblastoma (WHO grade IV), respectively. In patients with low-grade glioma, age, preoperative Karnofsky performance scale (KPS), pathological type, radiotherapy, O6-methylguanine-DNA methyltransferase (MGMT) expression and Ki-67 expression, were significantly associated with OS in multivariate analyses; and preoperative KPS and radiotherapy were significantly associated with progression-free survival (PFS). For anaplastic gliomas, age, preoperative KPS, pathological type, extent of resection, radiotherapy, p53 expression and phosphatase and tensin homolog (PTEN) expression were associated with OS. For glioblastomas, age, preoperative KPS, pathology type, extent of resection, radiotherapy and chemotherapy were associated with OS; and age, gender, preoperative KPS, extent of resection, radiotherapy and chemotherapy were associated with PFS. This is the largest survey for glioma management in China to date. We found significant differences in age, presenting symptoms and the expression of p53, MGMT, PTEN, and Ki-67 among patients with different types of glioma. Age, preoperative KPS, tumor grades, radiotherapy, chemotherapy and Ki-67 expression were significantly associated with clinical prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109(1):93–108. doi:10.1007/s00401-005-0991-y

    Article  PubMed  Google Scholar 

  2. Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet A, Tourdias T, Kantor G, Maire JP, Vital A, Loiseau H (2011) Descriptive epidemiology of CNS tumors in France: results from the Gironde registry for the period 2000–2007. Neuro-Oncology 13(12):1370–1378. doi:10.1093/neuonc/nor120

    Article  PubMed  CAS  Google Scholar 

  3. Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf GT, Worden F (2011) National comprehensive cancer network clinical practice guidelines in oncology: head and neck cancers. J Natl Compr Cancer Netw (JNCCN) 9(6):596–650

    Google Scholar 

  4. Stupp R, Pavlidis N, Jelic S (2005) ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol 16(Suppl 1):i64–i65. doi:10.1093/annonc/mdi834

    Article  PubMed  Google Scholar 

  5. Chang SM, Parney IF, Huang W, Anderson FA Jr, Asher AL, Bernstein M, Lillehei KO, Brem H, Berger MS, Laws ER (2005) Patterns of care for adults with newly diagnosed malignant glioma. J Am Med Assoc (JAMA) 293(5):557–564. doi:10.1001/jama.293.5.557

    Article  CAS  Google Scholar 

  6. Thurnher MM (2009) 2007 World Health Organization classification of tumours of the central nervous system. Cancer imaging: the official publication of the International Cancer Imaging Society 9 Spec No. A:S1–3. doi:10.1102/1470-7330.2009.9001

  7. Korshunov A, Golanov A, Sycheva R (2002) Immunohistochemical markers for prognosis of cerebral glioblastomas. J Neuro-Oncol 58(3):217–236

    Article  Google Scholar 

  8. Brell M, Tortosa A, Verger E, Gil JM, Vinolas N, Villa S, Acebes JJ, Caral L, Pujol T, Ferrer I, Ribalta T, Graus F (2005) Prognostic significance of o 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11(14):5167–5174. doi:10.1158/1078-0432.CCR-05-0230

    Article  PubMed  CAS  Google Scholar 

  9. Kujas M, Lejeune J, Benouaich-Amiel A, Criniere E, Laigle-Donadey F, Marie Y, Mokhtari K, Polivka M, Bernier M, Chretien F, Couvelard A, Capelle L, Duffau H, Cornu P, Broet P, Thillet J, Carpentier AF, Sanson M, Hoang-Xuan K, Delattre JY (2005) Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 58(2):322–326. doi:10.1002/ana.20543

    Article  PubMed  CAS  Google Scholar 

  10. Stupp R, Roila F (2009) Malignant glioma: eSMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):126–128. doi:10.1093/annonc/mdp151

    PubMed  Google Scholar 

  11. Scoccianti S, Magrini SM, Ricardi U, Detti B, Buglione M, Sotti G, Krengli M, Maluta S, Parisi S, Bertoni F, Mantovani C, Tombolini V, De Renzis C, Lioce M, Fatigante L, Fusco V, Muto P, Berti F, Rubino G, Cipressi S, Fariselli L, Lupattelli M, Santoni R, Pirtoli L, Biti G (2010) Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery 67(2):446–458. doi:10.1227/01.NEU.0000371990.86656.E8

    Article  PubMed  Google Scholar 

  12. Kang SG, Kim JH, Nam DH, Park K (2005) Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol medico-chirurgica 45(5):232–238 discussion 238–239

    Article  Google Scholar 

  13. Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J (2003) Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol 129(8):477–484. doi:10.1007/s00432-003-0471-5

    Article  PubMed  Google Scholar 

  14. Tramacere F, Gianicolo E, Serinelli M, Bambace S, De Luca M, Castagna R, Francavilla MC, Leone A, Monastero S, Fucilli F, Pili G, Distante A, Portaluri M (2008) Multivariate analysis of prognostic factors and survival in patients with “glioblastoma multiforme”. La Clin terap 159(4):233–238

    CAS  Google Scholar 

  15. You G, Sha ZY, Yan W, Zhang W, Wang YZ, Li SW, Sang L, Wang Z, Li GL, Song YJ, Kang CS, Jiang T (2012) Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro-Oncology 14(2):230–241. doi:10.1093/neuonc/nor205

    Article  PubMed  Google Scholar 

  16. Li S, Jiang T, Li G, Wang Z (2008) Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. Neurol Res 30(6):567–570. doi:10.1179/174313208X297913

    Article  PubMed  CAS  Google Scholar 

  17. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981–22981/CE.3. Lancet Oncol 9(1):29–38. doi:10.1016/S1470-2045(07)70384-4

    Article  PubMed  Google Scholar 

  18. Zhang W, Zhang J, Yan W, You G, Bao Z, Li S, Kang C, Jiang C, You Y, Zhang Y, Chen CC, Song SW, Jiang T (2012) Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer. doi:10.1002/cncr.27826

    Google Scholar 

  19. Zhang W, Yan W, You G, Bao Z, Wang Y, Liu Y, You Y, Jiang T (2013) Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma. Cancer Lett 328(1):120–125. doi:10.1016/j.canlet.2012.08.033

    Article  PubMed  CAS  Google Scholar 

  20. Yan W, Zhang W, You G, Zhang J, Han L, Bao Z, Wang Y, Liu Y, Jiang C, Kang C, You Y, Jiang T (2012) Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro-Oncology 14(12):1432–1440. doi:10.1093/neuonc/nos263

    Article  PubMed  CAS  Google Scholar 

  21. Wang Y, Li S, Chen L, You G, Bao Z, Yan W, Shi Z, Chen Y, Yao K, Zhang W, Kang C, Jiang T (2012) Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro-Oncology 14(4):518–525. doi:10.1093/neuonc/nor232

    Article  PubMed  Google Scholar 

  22. Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T (2012) Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro-Oncology 14(1):109–116. doi:10.1093/neuonc/nor185

    Article  PubMed  CAS  Google Scholar 

  23. Chen L, Han L, Zhang K, Shi Z, Zhang J, Zhang A, Wang Y, Song Y, Li Y, Jiang T, Pu P, Jiang C, Kang C (2012) VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1alpha/VEGF and beta-catenin/Tcf-4 signaling. Neuro-Oncology 14(8):1026–1036. doi:10.1093/neuonc/nos122

    Article  PubMed  CAS  Google Scholar 

  24. Zhang J, Huang K, Shi Z, Zou J, Wang Y, Jia Z, Zhang A, Han L, Yue X, Liu N, Jiang T, You Y, Pu P, Kang C (2011) High beta-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression. Neuro-Oncology 13(6):600–609. doi:10.1093/neuonc/nor034

    Article  PubMed  CAS  Google Scholar 

  25. Burton EC, Prados MD (2000) Malignant gliomas. Curr Treat Options Oncol 1(5):459–468

    Article  PubMed  CAS  Google Scholar 

  26. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95(2):190–198. doi:10.3171/jns.2001.95.2.0190

    Article  PubMed  CAS  Google Scholar 

  27. Sawaya R (1999) Extent of resection in malignant gliomas: a critical summary. J Neuro-Oncol 42(3):303–305

    Article  CAS  Google Scholar 

  28. Li S, Zhang W, Chen B, Jiang T, Wang Z (2010) Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy. Neurol Res 32(7):690–694. doi:10.1179/016164109X12478302362536

    Article  PubMed  Google Scholar 

  29. Westermark B (2012) Glioblastoma–a moving target. Upsala J Med Sci 117(2):251–256. doi:10.3109/03009734.2012.676574

    Article  PubMed  Google Scholar 

  30. Fedrigo CA, Grivicich I, Schunemann DP, Chemale IM, dos Santos D, Jacovas T, Boschetti PS, Jotz GP, Braga AF, da Rocha AB (2011) Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr. Radiat Oncol 6:156. doi:10.1186/1748-717X-6-156

    Article  PubMed  CAS  Google Scholar 

  31. Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, Kang C, You Y, Jiang C, Song SW, Jiang T, Chen CC (2012) miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-Oncology 14(6):712–719. doi:10.1093/neuonc/nos089

    Article  PubMed  CAS  Google Scholar 

  32. Hagerstrand D, Lindh MB, Pena C, Garcia-Echeverria C, Nister M, Hofmann F, Ostman A (2010) PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. Neuro-Oncology 12(9):967–975. doi:10.1093/neuonc/noq029

    Article  PubMed  Google Scholar 

  33. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, DePinho RA (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455(7216):1129–1133. doi:10.1038/nature07443

    Article  PubMed  CAS  Google Scholar 

  34. Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA (2007) A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67(17):7960–7965. doi:10.1158/0008-5472.CAN-07-2154

    Article  PubMed  CAS  Google Scholar 

  35. Wei Q, Clarke L, Scheidenhelm DK, Qian B, Tong A, Sabha N, Karim Z, Bock NA, Reti R, Swoboda R, Purev E, Lavoie JF, Bajenaru ML, Shannon P, Herlyn D, Kaplan D, Henkelman RM, Gutmann DH, Guha A (2006) High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res 66(15):7429–7437. doi:10.1158/0008-5472.CAN-06-0712

    Article  PubMed  CAS  Google Scholar 

  36. Maier D, Jones G, Li X, Schonthal AH, Gratzl O, Van Meir EG, Merlo A (1999) The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res 59(21):5479–5482

    PubMed  CAS  Google Scholar 

  37. Paulus W (2009) GFAP, Ki67 and IDH1: perhaps the golden triad of glioma immunohistochemistry. Acta Neuropathol 118(5):603–604. doi:10.1007/s00401-009-0600-6

    Article  PubMed  Google Scholar 

  38. Laperriere N, Zuraw L, Cairncross G (2002) Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64(3):259–273

    Article  PubMed  Google Scholar 

  39. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926. doi:10.1016/S1470-2045(12)70265-6

    Article  PubMed  Google Scholar 

  40. Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O’Brien JM, Cetingoz E, Da Fonseca E, Creasy GW, Klein K, Rode L, Soma-Pillay P, Fusey S, Cam C, Alfirevic Z, Hassan SS (2012) Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J obstet Gynecol 206(2):e119–e121. doi:10.1016/j.ajog.2011.12.003

    Article  Google Scholar 

  41. Grossman SA, O’Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, Gilbert M, Newton HB, Hellman R (2003) Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21(8):1485–1491. doi:10.1200/JCO.2003.10.035

    Article  PubMed  CAS  Google Scholar 

  42. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330

    Article  PubMed  CAS  Google Scholar 

  43. Kleihues P, Sobin LH (2000) World Health Organization classification of tumors. Cancer 88(12):2887

    Article  PubMed  CAS  Google Scholar 

  44. Smoll NR, Gautschi OP, Schatlo B, Schaller K, Weber DC (2012) Relative survival of patients with supratentorial low-grade gliomas. Neuro-Oncology 14(8):1062–1069. doi:10.1093/neuonc/nos144

    Article  PubMed  Google Scholar 

  45. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479–489

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Yuling Yang for the collection of tissue samples and the retrieval of clinical data. National Key Project of Science and Technology Supporting Programs of China (No. 2007BAI05B08), National Basic Research Program of China (973 Program) (No. 2010CB529406, 2011CB707804).

Conflict of interest

  No potential conflicts of interest were disclosed.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing, 100050, China

    Pei Yang, Yongzhi Wang, Gan You, Wei Zhang, Wei Yan, Zhaoshi Bao, Yinyan Wang, Xiaoguang Qiu & Tao Jiang

  2. Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing, 100050, China

    Pei Yang, Yongzhi Wang, Wei Yan, Zhaoshi Bao, Yinyan Wang & Tao Jiang

  3. Department of Epidemiology and Biostatistics, School of Public Health and Family Medicine, Capital Medical University, Beijing, 100069, China

    Xiaoxia Peng

  4. Department of Neurosurgery, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China

    Pei Yang, Yongzhi Wang, Xiaoxia Peng, Gan You, Wei Zhang, Wei Yan, Zhaoshi Bao, Yinyan Wang, Xiaoguang Qiu & Tao Jiang

Authors
  1. Pei Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yongzhi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoxia Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gan You
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhaoshi Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yinyan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiaoguang Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tao Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tao Jiang.

Additional information

Pei Yang and Yongzhi Wang contributed equally to this study.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 38 kb)

Supplementary material 2 (PPTX 551 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, P., Wang, Y., Peng, X. et al. Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution. J Neurooncol 113, 259–266 (2013). https://doi.org/10.1007/s11060-013-1103-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-013-1103-9

Keywords

Search

Navigation